Opinion

Video

Treatment Sequencing With Androgen Receptor-Targeted Therapies for mCRPC

Author(s):

Gautam Jayram, MD,Christopher Pieczonka, MD

Key opinion leaders discuss considerations for sequencing androgen receptor-targeted therapies in metastatic castration-resistant prostate cancer, evaluating their benefits in first-line versus second-line treatment settings.

When treating with androgen receptor-targeted therapies, what are some of the considerations to make towards the sequencing of these agents and weighing their benefits in first line versus second line?

Related Videos
Oliver Sartor, MD, is featured in this series.
Man talking with doctor, who is taking notes on a clipboard | Image Credit: © DragonImages - stock.adobe.com
Oliver Sartor, MD, is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Michael Jenson, PA-C, answers a question during a Zoom video interview
Oliver Sartor, MD, is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Related Content
ECLIPSE trial: 177Lu-PSMA-I&T extends rPFS vs hormone therapy in mCRPC
November 13th 2024

ECLIPSE trial: 177Lu-PSMA-I&T extends rPFS vs hormone therapy in mCRPC

Hannah Clarke
Final completion of the ECLIPSE trial is anticipated for February 2029.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Phase 1/2 trial of ONCT-534 in mCRPC has been terminated
November 7th 2024

Phase 1/2 trial of ONCT-534 in mCRPC has been terminated

Hannah Clarke
The decision was based on an interim readout from the trial, which showed that ONCT-534 did not lead to any clinically meaningful improvement of disease.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Phase 2 trial of masofaniten plus enzalutamide in mCRPC has been terminated
November 1st 2024

Phase 2 trial of masofaniten plus enzalutamide in mCRPC has been terminated

Hannah Clarke
The decision comes after a pre-specified futility analysis determined that it was unlikely that the study would meet its primary end point.
NDA submitted for 3-month formulation of leuprolide mesylate for advanced prostate cancer
October 30th 2024

NDA submitted for 3-month formulation of leuprolide mesylate for advanced prostate cancer

Hannah Clarke
The NDA submission is supported by data from a single-arm, phase 3 trial of leuprolide mesylate administered as 2 injections, 3 months apart.
© 2024 MJH Life Sciences

All rights reserved.